capecitabine (Xeloda)
Jump to navigation
Jump to search
Indications
- metastatic colon carcinoma (FDA approved)*
- stage IV breast cancer (2nd-4th line agent)[2]*
- inoperable advanced gastric cancer - in combination with a platinum-based regimen
- ovarian cancer[3]
- pancreatic adenocarcinoma
- islet cell tumor[3]
* Generic FDA-approved September 2013[2]
Dosage
Adverse effects
- diarrhea, nausea/vomiting
- pain, redness, swelling, or sores in the mouth
- hand-&-foot syndrome
- more likely than 5-FU to cause pain & swelling of the hands & feet
- loss of fingerprints has been reported[4]
- cutaneous lupus erythematosus[5]
- fever or infection Drug interactios:
Mechanism of action
- metabolized to 5-fluorouracil (5-FU)
- similar therapeutic effect as 5-FU
More general terms
Additional terms
Component of
References
- ↑ Prescriber's Letter 8(7):40 2001
- ↑ 2.0 2.1 2.2 2.3 FDA News Release: Sept. 16, 2013 FDA approves first generic capecitabine to treat colorectal and breast cancers
- ↑ 3.0 3.1 3.2 Deprecated Reference
- ↑ 4.0 4.1 Chavarri-Guerra Y, Soto-Perez-de-Celis E Images in clinical medicine. Loss of fingerprints. N Engl J Med. 2015 Apr 16;372(16):e22 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25875278 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMicm1409635
- ↑ 5.0 5.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015